Immunocytochemistry for choline acetyltransferase (ChAT) and the vesicular acetylcholine
transporter (VAChT) was used to examine the expression of these linked cholinergic …

1. Although the physical nature of sigma (σ) receptors have not yet been fully defined,
several classes of selective ligands have been characterised, demonstrating a plethora of …

Behavioural and psychological symptoms of dementia (BPSD) occur in 50–90% of
Alzheimer's disease (AD) patients. Imbalance of different neurotransmitters (acetylcholine …

Learn the therapeutic skills you need for your role in psychiatric nursing care! Psychiatric
Nursing uses a practical, three-pronged approach to psychotherapeutic management that …

The book begins with the history of Alzheimer's disease (AD), followed by clinical
considerations in diagnosis, psychiatry and psychology, clinical genetics, imaging …

Galanthamine (or galantamine, Reminyl®) is a tertiary alkaloid acetylcholinesterase inhibitor
(AChEI) which has been approved in several countries for the symptomatic treatment of …

Cholinesterase inhibitors (ChE-Is) are the standard of therapy for treatment of patients with
Alzheimer disease (AD) and are the only class of drugs approved by the Food and Drug …

The human cytochrome P450 enzyme system metabolises a wide array of xenobiotics to
pharmacologically inactive metabolites, and occasionally, to toxicologically active …

This review starts with an historical background of the pharmacological development of
tacrine almost fifty years ago (1949). Tacrine is the first drug to be tested, clinically, on a …

Background Behavioral abnormalities are common in Alzheimer disease (AD); cholinergic
treatment reduces the behavioral disturbances of some patients with AD. Characterizing the …